The drugmaker’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull ...

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

South Korea’s newest billionaire is Lee Sang-hoon, founder of ABL Bio, after it struck a $2.6 billion licensing and joint ...

Eli Lilly partners with ABL Biotech on bispecific antibodies via the Grabody platform in a deal worth up to $2.6B. Read more ...

Eli Lilly is poised to become the first $1 trillion pharmaceutical company, driven by explosive growth in its weight-loss ...

A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to ...

For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.

Historical trends show that even leading firms can experience abrupt market fluctuations, where stocks can plummet ...

In the preceding three months, 12 analysts have released ratings for Eli Lilly (NYSE: LLY ), presenting a wide array of perspectives from bullish to bearish. The following table summarizes their ...

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...